Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes

NCT ID: NCT00102245

Last Updated: 2018-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

334 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-18

Study Completion Date

2017-08-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine blood for factors that may cause or prevent diseases involving iron or red blood cells. Iron is an important nutrient for human health that is needed to produce red blood cells. Red blood cells carry oxygen to body tissues. A better understanding of iron and red blood cells may help lead to better treatment of several diseases including anemia.

Patients of all ages with red cell abnormalities in the following categories may be eligible for this study:

* Diseases with deficiency, overload or maldistribution of iron
* Known red blood cell diseases, such as anemias and hemoglobinopathies
* Red blood cell diseases of unknown cause, such as hemolysis of unknown cause
* Red blood cell abnormalities with no overt clinical disease, such as hereditary persistence of fetal hemoglobin

Participants undergo the following procedures:

* Medical history
* Physical examination
* Standard medical tests related to the individual's iron or red blood cell condition

Blood draw for the following purposes:

* Testing for syphilis and for the hepatitis B and C, HIV, and HTLV-1viruses, and for a pregnancy test for women who can become pregnant
* Research purposes. This blood is analyzed for genes, proteins, sugars, and fat molecules.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studies of iron and erythroid cells, have provided fundamental insights into structure function relationships of proteins, energy metabolism, and the molecular basis of many diseases. Based upon the importance of iron for hemoglobin production, the regulation of erythropoiesis and iron metabolism are closely linked, and iron deficiency anemia remains as one of the most common diseases worldwide. The discovery of sickle hemoglobin as having an abnormal electrophoretic mobility marked the beginning of the molecular medicine era. The advent of recombinant DNA technology and sequencing methodologies resulted in the characterization of erythroid cells well beyond that of protein based studies to include gene structure and expression. Globin gene research, in particular, has provided a wealth of information about the expression, regulation and insulation of mammalian genes. More recently, studies of iron absorption and trafficking provided new avenues of research aimed toward growth and energy homeostasis. Genome based approaches were also utilized for the discovery of direct relationships between erythroid cell biology and iron homeostasis. Hence, there is strong evidence that fundamental clinical advances in the field of iron and erythroid biology have been based upon the careful study of humans with informative phenotypes. Clinically based correlation of genotype and phenotype is a proven, systematic approach for understanding the molecular basis of disease.

With the completion of the sequencing of the human genome, a more complete, genetically based description of disease is now achievable. Efforts aimed toward haplotype mapping will further enhance genotype phenotype correlation directly from clinical samples. Considerable progress has already been made in this regard using normal human erythroid cells. In contrast to classic studies involving single genes or proteins, computational biology and high throughput technologies permit the analysis of complex erythroid phenotypes including those with related iron pathologies. This information will be invaluable for understanding those molecular mechanisms that are altered in disease states.

The immediate aim of this protocol is to perform phenotypic analyses in humans with informative iron or erythroid phenotypes. These studies are expected to result in detailed clinical phenotyping and the collection and banking of clinical specimens for further study. In addition, we predict an ongoing growth of new technologies that may eventually be used for molecular and genetic phenotyping of clinical samples (examples include oligonucleotide chips and high throughput mass spectroscopy). Based upon this prediction, we plan to use the samples collected here to assess possible clinical uses of those technologies as they become available. The eventual aim is the discovery of identifiers that may be predictive of disease pathogenesis, severity or clinical response to intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemoglobinopathies Hemolysis Iron Deficiency and Overload Anemias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A clinically definable iron or erythroid cell phenotype as defined by:

Group 1: Patients with known iron or erythroid diseases (examples: iron deficient anemia or ineffective erythropoiesis).

OR

Group 2: Patients with diseases of unknown etiology (example: unexplained iron overload or anemia).

OR

Group 3: Patients with an informative phenotype in the absence of overt clinical disease (example: hereditary persistence of fetal hemoglobin).

OR

Group 4: Healthy volunteers whose blood or bone marrow samples will be utilized to understand normal iron and erythroid biology and for comparison with the other groups described above.

AGE AND GENDER CONSIDERATIONS:

* Age range: Infancy to unlimited
* Adults: Adults who fall into Groups 1-4 are eligible to enroll in this protocol. They must possess the ability to comprehend the investigational nature of the study and provide informed consent.
* Minors: Minors who fall into groups 1-4 are eligible to enroll in the study for collection of research blood. Within Group 4 (healthy volunteers, minors), the research will not involve greater than minimal risk.

Exclusion Criteria

Healthy volunteers and Subjects with iron or erythroid diseases who are unable to comprehend the investigational nature of the laboratory research are ineligible to enroll in this protocol.
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeffery L Miller, M.D.

Role: PRINCIPAL_INVESTIGATOR

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Goh SH, Josleyn M, Lee YT, Danner RL, Gherman RB, Cam MC, Miller JL. The human reticulocyte transcriptome. Physiol Genomics. 2007 Jul 18;30(2):172-8. doi: 10.1152/physiolgenomics.00247.2006. Epub 2007 Apr 3.

Reference Type BACKGROUND
PMID: 17405831 (View on PubMed)

Gubin AN, Njoroge JM, Wojda U, Pack SD, Rios M, Reid ME, Miller JL. Identification of the dombrock blood group glycoprotein as a polymorphic member of the ADP-ribosyltransferase gene family. Blood. 2000 Oct 1;96(7):2621-7.

Reference Type BACKGROUND
PMID: 11001920 (View on PubMed)

Gubin AN, Njoroge JM, Bouffard GG, Miller JL. Gene expression in proliferating human erythroid cells. Genomics. 1999 Jul 15;59(2):168-77. doi: 10.1006/geno.1999.5855.

Reference Type BACKGROUND
PMID: 10409428 (View on PubMed)

Miller JL. Signaled expression of fetal hemoglobin during development. Transfusion. 2005 Jul;45(7):1229-32. doi: 10.1111/j.1537-2995.2005.00182.x. No abstract available.

Reference Type BACKGROUND
PMID: 15987371 (View on PubMed)

Goh SH, Lee YT, Bhanu NV, Cam MC, Desper R, Martin BM, Moharram R, Gherman RB, Miller JL. A newly discovered human alpha-globin gene. Blood. 2005 Aug 15;106(4):1466-72. doi: 10.1182/blood-2005-03-0948. Epub 2005 Apr 26.

Reference Type BACKGROUND
PMID: 15855277 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

05-DK-0085

Identifier Type: -

Identifier Source: secondary_id

050085

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Anemia in the Elderly
NCT00640172 COMPLETED